|
|
|
| Effect of Thymosin Adjuvant Therapy on the Treatment Effect of Diabetic Patients with Pulmonary Tuberculosis and the Effect of Serum Immune Cell Level |
| KUANG Jianren |
| The Affiliated Southwest Hospital of the Army Military Medical University, Chongqing Shaping Distric 400038, China |
|
|
|
|
Abstract Objective: To investigate the effect of immune cells and serum level of clinical effect in patients with Thymopeptide Enteric Injection adjuvant treatment of diabetes complicated with pulmonary tuberculosis. Methods: 98 cases of diabetic patients with tuberculosis infection in our hospital from June 2014 to June 2016, diagnosed by T-spot TB in, according to the principle of voluntary patients were divided into the control group and the control group with conventional therapy combined with thymosin adjuvant therapy, immune cell level contrast effect, the treatment group of two patients with tuberculosis in serum. Results:In the observation group, the duration of intensive treatment and the end of treatment were 37 and 42 cases, respectively. There were 36 cases and 41 cases of negative culture. There was no difference between the control group and the control group, P>0.05. The level of serum immune cells in patients with different types of contrast, found that the normal serum level of Treg cells was 1.3±0.6, significantly lower than those in patients with diabetes and diabetes combined with pulmonary tuberculosis, and the level of Th17 cells was 3.5±1.2, significantly higher than that in patients with diabetes and diabetes combined with pulmonary tuberculosis was significantly different, There was no difference in the level of Treg cell nuclear Th17 cells in the two groups before treatment, which was comparable. There was no difference in the incidence of symptoms between the two groups after treatment. After treatment, the disappearance rate of fatigue, night sweats, loss of appetite, cough and sputum in the observation group were 88.89%, 87.10%, 86.36%, 75%, 88.89%, which was significantly higher than that in the control group, with significant difference. Conclusion: While strengthening the anti-tuberculosis treatment, thymosin injection can improve the immune function of patients, help to improve the T cell subsets and promote the relief of clinical symptoms, which is worthy of clinical promotion and application.
|
|
|
|
|
|
[1] 杨帆,胡蕴,朱蕴庆,等.糖尿病慢性肾脏疾病患者外周血免疫调节T淋巴细胞比例异常的临床观察[J].中国糖尿病杂志,2016,24(11):972~977.
[2] 田俊萍,王鸿,王红霞,等.糖尿病和非糖尿病的缺血性卒中患者血压昼夜节律与预后的关系[J].首都医科大学学报,2016,37(1):62~69.
[3] 张放,杨飞.糖尿病合并肺结核患者肺部病灶组织中细胞因子的表达及意义[J].中国医科大学学报,2014,43(4):313~315,319.
[4] 冉燕,陈玲,罗亚文,等.干扰素诱导蛋白-10和肿瘤坏死因子-α在肺结核合并糖尿病患者中的表达及意义[J].广东医学,2013,34(20):3180~3181.
[5] 黄莉,张燕飞.糖尿病伴慢性肾脏病的临床病理分析[J].重庆医学,2016,45(32):4572~4574.
[6] 于冰,俞娉,李利,等.2型糖尿病患者并发感染与体内免疫功能改变的关系[J].中国基层医药,2016,23(5):690~694.
[7] 游明元,李群,王晓霞,等.慢性阻塞性肺疾病合并Ⅱ型糖尿病患者的免疫功能变化及意义[J].西部医学,2015,27(10):1508~1510.
[8] 张雷,聂春兰,侯莹,等.胸腺肽对恶性肿瘤患者外周血免疫细胞功能的影响[J].中外医学研究,2015,13(34):20~21. |
|
|
|
2018, Vol. 24 
